How to buy Regeneron Pharmaceuticals (REGN) shares in Australia

Learn how to easily invest in Regeneron Pharmaceuticals shares.

Regeneron Pharmaceuticals, Inc
NASDAQ: REGN - USD
BIOTECHNOLOGY
$586.35
-$0.53 (-0.09%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Regeneron Pharmaceuticals, Inc is a biotechnology business with stocks listed in the US. Regeneron Pharmaceuticals shares (REGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$511.89 – an increase of 1.88% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Regeneron Pharmaceuticals

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Regeneron Pharmaceuticals. Find the share by name or ticker symbol: REGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Regeneron Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$586.88, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Regeneron Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Regeneron Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Regeneron Pharmaceuticals stock price (NASDAQ:REGN)

Use our graph to track the performance of REGN stocks over time.

Regeneron Pharmaceuticals shares at a glance

Information last updated 2021-07-22.
52-week rangeUS$441 - US$660
50-day moving average US$550.2971
200-day moving average US$505.4998
Target priceUS$638.39
PE ratio 16.7638
Dividend yield N/A (0%)
Earnings per share (TTM) US$35.128

Compare share trading platforms to buy stock

Name Product Ratings Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro (global stocks)
Finder's rating
★★★★★
US$0
US$10 per month if there’s been no login for 12 months
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
Finder's rating
★★★★★
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
Not yet rated
US$0
No
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares, ETFs
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
CMC Markets Stockbroking
Finder's rating
★★★★★
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
Saxo Capital Markets (Classic account)
Finder's rating
★★★★★
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Regeneron Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Regeneron Pharmaceuticals price performance over time

Historical closes compared with the last close of $511.89

1 week (2021-07-15) -13.14%
1 month (2021-06-25) -7.02%
3 months (2021-04-26) 2.14%
6 months (2021-01-22) -4.81%
1 year (2020-07-22) -19.71%
2 years (2019-07-22) 72.63%
5 years (2016-07-22) 30.80%

Stocks similar to Regeneron Pharmaceuticals

Is Regeneron Pharmaceuticals under- or over-valued?

Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Regeneron Pharmaceuticals's P/E ratio

Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Regeneron Pharmaceuticals shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Regeneron Pharmaceuticals's PEG ratio

Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.178. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Regeneron Pharmaceuticals's EBITDA

Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$4 billion (£2.9 billion).

The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Regeneron Pharmaceuticals financials

Revenue TTM US$9 billion
Operating margin TTM 41.15%
Gross profit TTM US$4.5 billion
Return on assets TTM 13.82%
Return on equity TTM 33.21%
Profit margin 44.43%
Book value 115.545
Market capitalisation US$62.7 billion

TTM: trailing 12 months

Shorting Regeneron Pharmaceuticals shares

There are currently 1.4 million Regeneron Pharmaceuticals shares held short by investors – that's known as Regeneron Pharmaceuticals's "short interest". This figure is 26.4% down from 1.9 million last month.

There are a few different ways that this level of interest in shorting Regeneron Pharmaceuticals shares can be evaluated.

Regeneron Pharmaceuticals's "short interest ratio" (SIR)

Regeneron Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Regeneron Pharmaceuticals shares currently shorted divided by the average quantity of Regeneron Pharmaceuticals shares traded daily (recently around 826444.44444444). Regeneron Pharmaceuticals's SIR currently stands at 1.71. In other words for every 100,000 Regeneron Pharmaceuticals shares traded daily on the market, roughly 1710 shares are currently held short.

However Regeneron Pharmaceuticals's short interest can also be evaluated against the total number of Regeneron Pharmaceuticals shares, or, against the total number of tradable Regeneron Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regeneron Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Regeneron Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0143% of the tradable shares (for every 100,000 tradable Regeneron Pharmaceuticals shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regeneron Pharmaceuticals.

Find out more about how you can short Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Regeneron Pharmaceuticals's total ESG risk score

Total ESG risk: 22.33

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 12/31/2018) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Regeneron Pharmaceuticals's environmental score

Environmental score: 1.51/100

Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Regeneron Pharmaceuticals's social score

Social score: 13.94/100

Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Regeneron Pharmaceuticals's governance score

Governance score: 5.88/100

Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Regeneron Pharmaceuticals's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Regeneron Pharmaceuticals, Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.33
Total ESG percentile 26.82
Environmental score 1.51
Environmental score percentile 2
Social score 13.94
Social score percentile 2
Governance score 5.88
Governance score percentile 2
Level of controversy 2

Regeneron Pharmaceuticals share dividends

We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.

Regeneron Pharmaceuticals share price volatility

Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as US$441 up to US$660. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.185. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).

Regeneron Pharmaceuticals overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform